

Placement Completed and Cleansing Notice

Melbourne, Australia: Bio-Gene Technology Limited (ASX:BGT or 'Bio-Gene' or 'the Company'), is pleased to announce that it has completed Tranche 2 of the placement of shares and SPP Underwriting previously announced on 26 May 2025 following approval by the Company's shareholders at the extraordinary general meeting held on 5 August 2026. Bio-Gene has issued 51,980,000 fully paid shares in the Company per the Appendix 2A's lodged today.

The issue of fully paid ordinary shares in the Company (**Shares**) under the Placement and the Share Purchase Plan (**SPP**) has raised gross proceeds of approximately A\$3.275 million (before costs).

In addition to the Shares issued under the Placement and SPP, shareholders also approved the issue of 69,221,150 Options exercisable at 3.5 cents per option, expiring 15 October 2027. The Options were issued to investors participating in the Placement, SPP, SPP Underwriting and the lead manager of the Placement.

Notice pursuant to Section 708A(5)(e) of the Corporations Act 2001

The Company gives notice (the **Notice**) pursuant to section 708A(5)(e) of the Corporations Act 2001 (Cth) (**Corporations Act**) that:

- the Company issued the Shares without disclosure to investors under Part 6D.2 of the Corporations Act;
- the Company is providing this Notice under section 708A(5)(e) of the Corporations Act;
- as at the date of this Notice, the Company has complied with:
 - the provisions of Chapter 2M of the Corporations Act as they apply to the Company; and
 - section 674 and Section 674A of the Corporations Act; and
- as at the date of this Notice, there is no excluded information within the meaning of section 708A(7) and 708A(8) of the Corporations Act.

Approved for release on ASX by Bio-Gene Board of Directors.

- ENDS -

For further information, please contact:

Bio-Gene Technology Limited:
E: bgt.info@bio-gene.com.au

Matthew Wright
NWR Communications
E: matt@nwrcommunications.com.au
M: 0451 896 420

About Bio-Gene Technology Limited

Bio-Gene is an Australian company developing novel bio-insecticides to address the global challenges of insecticide resistance and demand for natural insecticides. Its unique products are based on a naturally occurring class of compounds proven to overcome insecticide resistance to control pests with minimal impact on human health and the environment.

Bio-Gene's products have multiple applications across crop protection, grain storage, public health, animal health and consumer uses. They provide new options derived from nature to meet market demand for effective and safe pest management solutions.

www.bio-gene.com.au

Flavocide® and Qcide® are registered trademarks of Bio-Gene Technology Limited.
